Table 2.
ET-1 | ||||||
---|---|---|---|---|---|---|
LZR | OZR | |||||
pEC50 | Emax | n | pEC50 | Emax | n | |
Control | 9.22 ± 0.12 | 138 ± 7 | 6 | 9.56 ± 0.18f | 142 ± 7 | 7 |
+L-NOARG | 10.14 ± 0.18b | 121 ± 9 | 5 | 10.44 ± 0.22a | 123 ± 10 | 5 |
+L-NOARG -ENDO | 8.95 ± 0.15d | 150 ± 13 | 3 | 8.70 ± 0.18ad | 163 ± 9c | 4 |
+L-NOARG + apocynin | 8.92 ± 0.25d | 141 ± 14 | 4 | 8.92 ± 0.14d | 119 ± 7 | 4 |
Control-ENDO | 9.04 ± 0.20a | 165 ± 15a | 5 | 8.68 ± 0.16b | 203 ± 19b | 5 |
-ENDO + apocynin | 8.91 ± 0.16 | 156 ± 14 | 4 | 8.78 ± 0.18 | 139 ± 7e | 4 |
Values represent mean ± SEM of the number n of animals (one to two individual arteries from each animal were used). Significant differences from controls were analysed by one-way anova followed by Bonferroni as a posterio test or Student's t-test for unpaired observations.
P < 0.05;
P < 0.01 versus control.
P < 0.05;
P < 0.01 versus L-NOARG-treated.
P < 0.01 versus control-ENDO.
P < 0.05 versus LZR.